Publication » Vinorelbine (VNR), ifosfamide (IFO) and cisplatin (CDDP) as assitencial treatment in patients (PTS) with inoperable non small cell lung cancer (NSCLC).doi:10.1016/S0169-5002(00)80180-4J MontalarS MoralesC VadellI Maestu...
The study was carried out to compare the incidence of hematological toxicity between 14 cases with CDDP+VNR as first line therapy followed by CBDCA+PTX as ... K Morihata,M Kimura,K Okada,... - 《Gan to Kagaku Ryoho》 被引量: 7发表: 2010年 加载更多研究...
BACKGROUND The combination of vinorelbine (VNR), cisplatin (CDDP), and 5-fluorouracil (5-FU) has previously been shown to be active in recurrent and/or met... V Gebbia,G Mantovani,A Farris,... - 《Cancer》 被引量: 37发表: 2015年 Effect of consecutive lower-dose cisplatin in enhancemen...
结果:癌性胸腹水中的肿瘤细胞对抗癌药物的敏感性与药物的浓度呈正相关,在药物浓度为1×PPC时,癌性胸水对抗癌药物的敏感性依次为:NDP>CDDP>VNR>GEM>5-FU>MTA>... 陈娟 - 广州医科大学 被引量: 0发表: 2013年 胃癌中Survivin转录变异体的表达、及其与细胞增殖、凋亡、患者预后和化疗药物耐受的相关性研究 目的...
Phase II study of cisplatin (CDDP), ifosfamide (IFX) and vinorelbine (VNR) in stage-IIIB-IV NSCLCdoi:10.1016/0959-8049(94)90813-3E. BaldiniC. TibaldiA. ChellaC.A. AngelettiG. SilvanoP.F. ConteEuropean Journal of Cancer
A phase II study of induction CDDP+VNR+MMC followed by concomitant-boost thoracic radiotherapy with concurrent daily CDDP for unresectable locally advanced NSCLC (LA-NSCLC): P2-209Methadone maintenancecocaine usedaily activitypatterns of drug use...
Vinorelbine (VNR), ifosfamide (IFO) and cisplatin (CDDP) as assitencial treatment in patients (PTS) with inoperable non small cell lung cancer (NSCLC)doi:10.1016/s0169-5002(00)80180-4Montalar, JMorales, SVadell, CMaestu, ITorregrosa, M.D...
205 Phase I鈥揑I study of vinorelbine (VNR), cisplatin (CDDP) and mitomycin C (MMC) in non-small cell lung cancer (NSCLC)OgawaraFuruseNishiwakiTakadaFukuoka
Gemcitabine (GEM)-cisplatin (CDDP)-vinorelbine (VNR) combination in advanced non-small cell lung cancer (NSCLC): a phase II randomized study [abstract no. *1615]. Thirty-Third Annual Meeting, American Society of Clinical Oncologists; 1997 May 17–20; Denver, Vol. 16, 449a...
VNR, a novel semi-synthetic vinca alkaloid, is highly active in NSCLC patients (pts). Phase I-II study of VNR (20-25 mg/m2) with CDDP (80 mg/m2), and MMC (4 to 8 mg/m2) was conducted in previously untreated stage IIIB/IV NSCLC pts. VNR was administered on day 1 and 8, and...